Calidi Biotherapeutics, Inc., founded as a clinical-stage immuno-oncology company in Delaware, is developing a proprietary platform based on allogeneic stem cells to enhance and deliver oncolytic viruses and possibly molecules to cancer patients. The company is currently developing two proprietary stem cell-based platforms and an enveloped vaccinia virus platform designed to protect oncolytic viruses, both natural and engineered, from being neutralized by the patient's immune defenses, allowing tumor cells to be infected more and resulting in potential improvements in the anti-tumor activity of oncolytic viruses over traditional "naked" oncolytic virus therapies. 

CLDI

CLDI Profile